Agomab Therapeutics NV has 6 Schedule 13D or 13G filings on record since 2026-02-17. 6 holders' latest filing reports 5% or more of american depositary shares, each representing one common share, no nominal value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | 10.6% | 5,141,992 | SCHEDULE 13D, 2026-02-17 | 2026-02-09 |
| Fmr LLC | 10% | 4,873,680 | SCHEDULE 13G, 2026-03-06 | 2026-02-27 |
| Pontifax VI G.P. L.P. | 6.8% | 3,305,846 | SCHEDULE 13G, 2026-04-16 | 2026-03-31 |
| Sanofi | 5.71% | 2,783,096 | SCHEDULE 13G, 2026-05-06 | 2026-03-31 |
| Redmile Group, LLC | 5.6% | 2,735,926 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Cormorant Asset Management, LP | 5.01% | 2,465,348 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
Purpose of Transaction (Item 4)
LSP 7 Cooperatieve U.A.
Amended and Restated Shareholders' Agreement On November 4, 2024, certain shareholders of the Issuer, including LSP 7, entered into an amended and restated shareholders' agreement (the "Shareholders' Agreement") with the Issuer, pursuant to which the Issuer agreed, among other things, to register for resale certain Common Shares and other equity securities of the Issuer that are held by the parties (the "Registrable Securities"), and agreed to provide customary demand and "piggyback" registration rights, subject to certain requirements and conditions. The Shareholders' Agreement terminated immediately prior to the consummation of the IPO, except for the confidentiality provisions and registration rights granted thereunder. The registration rights granted under the Shareholders' Agreement will terminate upon the earlier of upon the earliest of one of the following three events: (1) a liquidity event, such as payment of dividends or a share buy-back, a bankruptcy or similar liquidation or dissolution, an asset sale or any merger or consolidation or acquisition of the Issuer; (2) such time as Rule 144 or another similar exemption under the Securities Act of 1933, as amended, is available for the sale of all of such holder's shares without limitation (including without observance of the manner of sale, volume limitation and notice provisions of Rule 144) during a three month period without registration; and (3) the third anniversary of the IPO. Lock-up Agreement In …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-17 | LSP 7 Cooperatieve U.A. | 10.6% | SCHEDULE 13D |
| 2026-03-06 | Fmr LLC | 10% | SCHEDULE 13G |
| 2026-04-16 | Pontifax VI G.P. L.P. | 6.8% | SCHEDULE 13G |
| 2026-05-06 | Sanofi | 5.71% | SCHEDULE 13G |
| 2026-05-15 | Redmile Group, LLC | 5.6% | SCHEDULE 13G |
| 2026-05-15 | Cormorant Asset Management, LP | 5.01% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Agomab Therapeutics NV. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.